Metastasis News and Research

RSS

Metastasis is the spread of cancer from one part of the body to another. A tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor. The plural form of metastasis is metastases

Reversing macrophage metabolism may improve cancer immunotherapy outcomes

Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the tumor microenvironment.

1 Jul 2026

Fatty liver disease fuels aggressive metastatic colorectal cancer spread

Researchers at VIB and KU Leuven, with international partners, have uncovered how fatty liver disease can fuel the most aggressive form of metastatic colorectal cancer.

1 Jul 2026

German study identifies therapeutic Achilles' heel for advanced colorectal cancer

A team led by researchers from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute has discovered a promising new approach to treating advanced colorectal cancer.

1 Jul 2026

Japanese study links inherited genetic variants to multiple lung cancers

Lung cancer remains the leading cause of cancer-related deaths worldwide and is generally thought to arise from mutations acquired over a lifetime through environmental exposures.

30 Jun 2026

Scientists map how cellular senescence and stemness interact in disease

A new review was published in Volume 18 of Aging on May 30, 2026, titled "The love and hate relationship between cellular senescence and stemness."

29 Jun 2026

AI and multiomics reveal how gut bacteria trigger colon cancer

Over the past two decades, high‑throughput sequencing has dramatically expanded our understanding of the gut microbiome's composition.

26 Jun 2026

Study uncovers mechanism driving metastasis in aggressive gastric cancer

A study recently published in Current Molecular Pharmacology has uncovered a novel mechanism by which the long non‑coding RNA PVT1 and the translation initiation factor EIF4A1 cooperate to drive gastric cancer metastasis.

25 Jun 2026

Natural bioactive compounds target miR-29a molecule to prevent cancer development

A study published in Current Molecular Pharmacology provides a comprehensive analysis of microRNA-29a (miR-29a) as a pivotal regulator in cancer development, and examines how natural bioactive compounds may offer a promising strategy for cancer prevention by modulating its expression.

25 Jun 2026

Scientists uncover new molecular mechanism driving gastrointestinal stromal tumors

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract, with KIT mutations driving approximately 75% to 80% of cases.

23 Jun 2026

Scientists discover how fat tissue drives the spread of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is aggressive and hard to treat. But the role of fat tissue in how the cancer spreads may help point toward new understanding and treatments, according to a new paper from scientists at the Hackensack Meridian Center for Discovery and Innovation (CDI) and colleagues at Georgetown University's Lombardi Comprehensive Cancer Center.

23 Jun 2026

GATA6 loss transforms colorectal cancer cells into metastatic states

Loss of GATA6-a transcription factor that controls which genes are turned on or off-can reprogram colorectal cancer cells into more primitive, adaptable states that can then spread to the liver and establish new tumors, according to Weill Cornell Medicine and Massachusetts Institute of Technology researchers.

22 Jun 2026

Brazilian researchers identify cell molecule that drives cancer progression

Researchers at the Federal University of São Paulo (UNIFESP) in Brazil have identified a molecule on the surface of cells that could be a promising therapeutic target against cancer.

18 Jun 2026

Tumor microenvironment drives drug resistance in lung cancer subtypes

A study by the University of Barcelona has discovered why the two main types of lung cancer — adenocarcinoma of the lung and squamous cell carcinoma — respond differently to anti-angiogenic therapy, that is, drugs that block the formation of new blood vessels that tumors need in order to grow.

15 Jun 2026

FDA approves new adjuvant treatment option for ccRCC patients with recurrence risk

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.

12 Jun 2026